GLP-1 prior authorization vs cash subscription: two approvals that mean different things
Prior authorization is a payer's pre-service coverage process; a cash subscription is a consumer contract for stated services. Neither proves that a drug is FDA approved, a prescription is clinically appropriate, a claim will be paid, or a compounded product is equivalent to an approved product.
GLP-1 prior authorization and a cash subscription answer different questions. Prior authorization is a payer’s review under a specific benefit, policy, product, diagnosis, and documentation rule. A cash subscription is a contract for listed services and perhaps medication. Neither record proves FDA approval, clinical appropriateness, final claim payment, pharmacy fulfillment, or equivalence between an approved product and a compounded one.123
The word “approved” is the main source of confusion. FDA approval concerns a drug product and use; insurer approval concerns coverage under plan terms; clinician approval concerns a prescription decision; subscription acceptance concerns a commercial relationship. Preserve each decision separately.
Build the pathway as seven records
| Stage | Controlling record | Common mistaken assumption |
|---|---|---|
| Clinical decision | Licensed prescriber's evaluation and prescription | Paying or qualifying online guarantees a prescription |
| Product status | FDA label or lawful compounding basis for the exact finished product | The ingredient name makes every vial FDA approved |
| Benefit | Current plan document and formulary | An insurance card means obesity treatment is covered |
| Prior authorization | Product- and patient-specific submission and decision | Authorization guarantees payment indefinitely |
| Claim and dispensing | Network, eligibility, pharmacy and claim facts on the fill date | An approval letter guarantees stock and a fixed copay |
| Cash contract | Subscription, medication, lab, refill and cancellation terms | A monthly fee includes every dose and service |
| Renewal or exit | Reauthorization, appeal, transition and record-transfer plan | Care continues automatically when coverage or membership ends |
Prior authorization belongs to one plan and moment
Ask for the exact benefit, formulary product, criteria, required diagnosis or clinical documentation, prescriber and pharmacy network, submission date, decision, effective period, renewal requirements, and appeal rights. A denial can concern an exclusion, missing information, step rule, product preference, or another plan term; it is not an FDA judgment about the drug.
CMS’s 2026 Medicare GLP-1 Bridge uses its own centralized process and defined criteria.12 It should not be presented as the workflow for an employer plan, marketplace plan, Medicaid program, or manufacturer offer. Even inside one program, provider approval, pharmacy claim, supply, and patient cost are separate events.
A cash subscription is not one standardized product
Request a dated schedule showing enrollment or consultation fee, clinician visits, medication, dose tiers, pharmacy, shipping, labs, nutrition services, messaging, refill work, missed visits, pauses, cancellation, refunds, and record transfer. Determine whether the medication charge is included, billed separately, or changes with dose.
If the service uses a compounded drug, document the pharmacy, formulation, concentration, container, beyond-use date, directions, and reason a compounded product is being prescribed. FDA’s 2026 actions against telehealth marketing underscore that a compounded product cannot be promoted as the same as or a generic version of an approved GLP-1 drug without a lawful and accurate basis.3 Compounded drugs are not FDA approved.
The provider-and-pharmacy guide follows the clinical supply chain. This article follows who pays and what happens when the payment path changes.
Compare four realistic scenarios
- Covered and approved Add premiums, deductible, copay or coinsurance, visits, labs, pharmacy and renewal work; include the possibility that the formulary changes.
- Covered but denied Record the reason, missing evidence, appeal deadline, interim clinical plan and whether cash payment affects an appeal or claim.
- Benefit exclusion Separate an exclusion from medical appropriateness and compare lawful cash options without pretending a prior authorization can override the plan.
- Cash subscription Price the entire contract through titration and maintenance, including medication identity, shipping, clinical access, cancellation and transfer.
Do not compare one insurance copay with one introductory subscription month. Normalize at least the likely first six months and a maintenance scenario, while acknowledging that dose, product, coverage and clinical plan may change.
Renewal is a clinical and financial handoff
Before starting, ask what data a payer or program requires at renewal and who collects it. Ask how the clinician handles a gap, intolerance, pregnancy planning, surgery, shortage, new diagnosis, coverage loss, or transition to another practice. A subscription cancellation should not erase access to the medical record or leave an active prescription with no owner.
For an online subscription, recurring-payment duties may come from ROSCA, the FTC Act, other applicable law and the contract; the FTC’s current Negative Option Rule itself covers only prenotification plans after the 2024 amendment was vacated.4 Keep the clinical stop or transfer plan independent from the billing cancellation steps.
The decisive question
Ask: “Which entity has approved which exact thing—drug, prescription, coverage, claim, or subscription—and what happens at renewal or loss of that approval?” If the answer remains “you’re approved,” the pathway is not documented.
Sources
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge information for providers. Current program-specific prior-authorization workflow illustrating that criteria, timing, prescribing and pharmacy steps are separate records. Accessed .
- Centers for Medicare & Medicaid Services. GLP-1 Bridge prescriber fact sheet. Primary federal fact sheet for the 2026 Bridge; not generalized to commercial insurance. Accessed .
- U.S. Food and Drug Administration. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Current federal enforcement record supporting exact product-status and marketing-claim verification. Accessed .
- Federal Trade Commission. Negative-option regulation after the vacated 2024 rule. Current FTC explanation that the bounded Negative Option Rule, FTC Act, ROSCA and Telemarketing Sales Rule remain distinct authorities after the 2024 amendment was vacated. Accessed .